This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. This series is based on the experiences we have encountered using valuation in actual negotiations with the various pitfalls that negotiators and valuation practitioners have while negotiating a deal.

Download This White Paper